AbbVie Down on Humira Patent Loss: Is More Damage in Store?

Shutterstock photo

AbbVie Inc. 's ABBV shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. CHRS .

So far this year, AbbVie's share price has increased 4.4%, comparing unfavorably with a gain of 9.4% recorded by the Zacks classified Large-Cap Pharma industry.

Coherus announced on Wednesday that it received a favourable ruling on an inter partes review (IPR) challenge to AbbVie's dosing patent '135 for Humira. The Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark office ruled to invalidate Humira's '135 patent, which covers the method of treating rheumatoid arthritis with subcutaneous doses of Humira 40mg bi-weekly.

Coherus is looking to get approval for a biosimilar version of Humira. Its shares shot up almost 8% on Wednesday.

Patent '135, which expires in Jun 2022, faces two additional IPR challenges from Boehringer Ingelheim, with rulings expected by early July.

The PTAB ruling did not come as a surprise as it was broadly expected. The investment community generally believes that AbbVie has a robust intellectual property (IP) portfolio beyond the '135 patent, which should preclude biosimilars from the U.S. market until 2022. Sales should continue to remain strong until then.

However, another group of investors comment that though the PTAB ruling was a minor hit for AbbVie, it still increases the chance of a biosimilar Humira launch earlier than expected.

Humira is key driver of Amgen's revenues, accounting for more than 60% of its total sales. The product continues to see strong growth in the dermatology and gastroenterology markets. Growing awareness, favorable clinical data, additional indications and expansion into new markets like China and Japan is helping the product contribute consistently to AbbVie's top line. The company expects Humira to bring in total sales of more than $18 billion in 2020.

However, several companies including Amgen, Inc. AMGN /Allergan plc AGN and Samsung Bioepis are working on biosimilar versions of Humira. Amgen's biosimilar version of Humira, Amjevita, was approved by the FDA in Sep 2016 and in the EU (trade name: Amgevita) in Mar 2017 for the same indications as Humira. However, Amgen is not expected to launch the drug at-risk amid litigation.

The entry of biosimilars will have a huge impact on the company's financials.

AbbVie carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Allergan PLC. (AGN): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Coherus BioSciences, Inc. (CHRS): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More